DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

A Clinical Study to Evaluate the Efficacy and Safety of DP303c versus trastuzumab emtansine in patients with HER2-positive Advanced Breast Cancer

Trial Details

NCT ID
NCT06313086
Phase
PHASE3
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • DP303c
  • trastuzumab emtansine
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • 1．Voluntarily agree to participate in the study and sign the informed consent;
  • 2．Age≥18 years old;
  • 3．Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology;
  • 4．Confirmed to be HER2 positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →